That's a likely yes as GTC licensed the CD137 program from the Mayo Clinic. FWIW, I believe they said at the time that this antibody might be used in large volumes and that requirement favors producing it transgenically.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.